2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
40
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
13
Neoplasms
12
Adenocarcinoma
11
Neoplasm Metastasis
10
Colorectal Neoplasms
9
Esophageal Neoplasms
7
Carcinoma, Hepatocellular
7
Colonic Neoplasms
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Adenocarcinoma Of Esophagus
5
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Rectal Neoplasms
3
Melanoma
3
Liver Neoplasms
3
Carcinoma, Transitional Cell
3
Biliary Tract Neoplasms
3
Ureteral Neoplasms
2
Thymoma
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Non-small Cell Lung Cancer Metastatic
2
Metastatic Gastric Adenocarcinoma
2
Interventions
tusamitamab ravtansine
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Gastric
×
Ramucirumab
×
Clear all
NCT05071053
2025-08-22
CARMEN-GC01
Sanofi
Phase 2
Terminated
35 enrolled
14 charts